← All trials
NCT04961528
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2021
- Primary completion
- Nov 15, 2023
- Completion date
- Dec 30, 2023
- First posted
- Jul 14, 2021
- Last posted
- Oct 4, 2021
- Enrollment
- 315
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Assistance Publique - Hôpitaux de ParisLead sponsor
- Government of FranceCollaborator
- Hôpital Européen Georges-PompidouStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.